
Genticel names Dr Didier Hoch, former president of Sanofi-Pasteur MSD, to its supervisory board

Toulouse, France, July 4, 2011 -- Genticel, a clinical biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), announces today that it has appointed Dr Didier Hoch as Member of the company's Supervisory Board (Conseil de Surveillance).

Dr Hoch brings his outstanding experience of over 25 years in the pharmaceutical industry to Genticel. Dr Hoch's successful career in the vaccine industry includes ten years as President of Sanofi-Pasteur – MSD, the joint venture of the vaccine businesses of Sanofi Aventis and Merck & Co., which launched one of the most successful vaccines ever: Gardasil, a preventive HPV vaccine. Dr Hoch is an expert in market access and launching of paradigm-shifting vaccines such as Gardasil, which transformed cervical cancer to a preventable viral disease.

Prior to his position as President of Sanofi-Pasteur MSD from 2000 until 2010, Didier Hoch was Vice President Africa & Middle East at Aventis Pharma International, and before that he was Deputy General Manager at Rhône-Poulenc Rorer France. From 2003 until 2009 Dr Hoch was President of the European Vaccine Manufacturers Association (EVM). He is currently an independent board member of TcL Pharma/Effimune (France) and Chairman of Pevion (Switzerland) In addition; Dr Hoch chairs the Biotechnology Committee of LEEM (the French pharma industry association) and is also President of the Life Science Health Committee of MEDEF (the major French industry association). He graduated in Medicine from the University of Lyon, France.

"Having Didier Hoch on our Board is a real asset for Genticel as he brings a thorough understanding of the vaccine business at large and the HPV-cervical cancer field in particular," said Thierry Hercend MD, PhD, Chairman of Genticel Supervisory Board. Dr Benedikt Timmerman, CEO of Genticel added: *"I'm looking forward to leveraging Didier's in-depth expertise in developing innovative vaccines. His arrival is timely for Genticel, which is conducting a large phase I clinical trial with ProCervix, our investigational vaccine for patients infected with HPV16 and/or 18, the two most frequent oncogenic HPV types."*

"Genticel is developing a highly promising vaccine and has a remarkable additional candidate following. I am very pleased to join the Supervisory Board and help the company position its strategic assets," said Dr Hoch.

Didier Hoch will join the Genticel Supervisory Board, which, besides Thierry Hercend, is composed of following members: Ludovic de Meeus d'Argenteuil, Vice-President of the Board and co-founder, Alain Munoz, MD, representing Kurma Life Sciences, Raphael Wisniewski, investment director at Edmond de Rothschild Investment Partners (EdRIP), Olivier Martinez, PhD, Investment Director, Life Sciences, CDC Entreprises, and Beatrice Llirbat, MD, PhD, partner of Amundi Private Equity Funds Life Science.

Picture available.

About Gentigel S.A.

Gentigel is a biopharmaceutical company that develops vaccines for patients already infected with Human Papillomavirus (HPV). The strategic goal of the company is to ensure that a vaccine solution can be offered to all women infected with high-risk HPV types, in order to prevent cervical cancers. Currently several pipeline candidates are being developed to make this possible.

ProCervix and pipeline candidates exploit the broadly applicable antigen-delivery platform based on recombinant Adenylate Cyclase (CyaA) protein. Gentigel licensed the CyaA technology from the Institut Pasteur for use in vaccines and immuno-therapeutics.

Gentigel (called BT Pharma until March 2010) raised EUR 19 M in capital since its inception, of which EUR 13.1 M during the last closing of February 2010. The company is incorporated in Toulouse, France and also has offices in Paris where clinical development is managed.

Visit our web site at www.gentigel.com

For further information on Gentigel, please contact:

Gentigel or Andrew Lloyd & Associates
Mme Yolande Misseri, Andrew Lloyd or Neil Hunter

Press Relations

Tel: +33 5 61 28 70 66

business@gentigel.com

Tel: +44 1273 675100

allo@ala.com / neil@ala.com